

6 May 2014
EMA/HMPC/198792/2012
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Arnica montana L., flos*

Final

The European Medicines Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Alonso D et al., Effects of topical Arnica gel on post-laser treatment bruises. Dermatol Surg, 2002, 28, 686-688

Berges C et al., Helenalin suppresses essential immune functions of activated CD4 cells by multiple mechanisms. Elsevier, 2009, doi: 10.1016

Bergonzi MC et al., Evaluation of skin permeability of sesquiterpenes of an innovative supercritical carbon dioxide arnica extract by HPLC/DAD/MS. Pharmazie, 2005, 60, 36-38

Brock FE, *Arnica montana* bei Venenleiden. Zeitschrift für Phytotherapie, 1991, 12, 141-145

Brock FE, Additiver Effekt venentypischer Hydrotherapie nach Kneipp und lokaler Arnika-Anwendungen bei patienten mitvenöser Insuffizienz-Synergismus naturheilkundlicher Therapien. Fachklinik für Rehabilitation und Gefäßerkrankungen, Kneippianum, 2001, 357-363

Chetak J, CGP Case report: drug interaction between warfarin and Arnica. Pharmacy Practise News, 2011, 37

CIR Expert Panel (2001) Final report on the safety assessment of *Arnica montana* extract and *Arnica montana*. Int J Toxicol 20 (Suppl 2): 1-11

Corazza M et al., Use of topical herbal remedies and cosmetics: a questionnaire-based investigation in dermatology out patients. Journal compilation European Academy of Dermatology and Venerology, 2009, 10.1111, 1468-3083

Delmonte S et al., Leukemia. Related Sweet's Syndrome elicited by pathergy to Arnica, Dermatology. 1998, 197, 195-196

Eberhartinger C, Beobachtungen zur Häufigkeit von Kontaktallergien. Z Hautkr, 1984, 59 (19) 1283-1289



Francois G, Claus M, Pseudoguaianolide sesquiterpene lactones with high activities against the human malaria parasite *Plasmodium falciparum*. *Phytotherapy Research*, 2004, 18, 184-186

Göggelmann W, Schimmer O, Mutagenic activity of phytotherapeutic drugs. *Prog Clin Biol Res*, 1986, 206, 63-72

Hausen BM, The sensitizing capacity of compositae plants. *Contact Dermatitis*, 1978, 4, 3-10

Hausen BM, The sensitizing capacity of compositae plants. *Dermatologica* 1979, 159, 1-11

Hausen BM, Arnikaallergie, *Der Hautarzt*, 1980, 31, 10-17

Hausen BM, Kokardenblumen-Allergie. *Dermatosen*, 1985, 33 (2), 62-68

Iauk L et al., Antibacterial activity of medical plant extracts against periodontopathic bacteria.

Phytotherapy Research, 2003, 17, 599-604

Jocher A et al., Allergic potential of Arnica-containing formulations in Arnica-allergic patients. *Contact Dermatitis*, 2009, 61, 304-306

Klaas CA et al., Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica flowers. *Planta med*, 2002, 68, 385-391

Knuesel O, Weber Michel Dr. Sc.Nat., Suter Andy M.Sc., *Arnica montana* gel in osteoarthritis of the knee: an open, multicenter clinical trial. *Advances in Therapy*, 2002, 19 (5), 209-218

Kos O et al., New sesquiterpene lactones from Arnica tincture prepared from fresh flowerheads of *Arnica montana*. *Planta med*, 2005, 71, 1044-1052

Lass C et al., Anti-inflammatory and immune-regulatory mechanisms prevent contact hypersensitivity in *Arnica montana* L.. *Experimental dermatology*, 2008, 17, 849-857

Leu S et al., Accelerated resolution of laser-induced bruising with topical 20% arnica: a rater-blinded randomized controlled trial. *British journal of Dermatology*, 2010, 163, 557-563

Lyss G et al., Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF- κ B. *Biol. Chem.* 1997, 378, 951-961

Merfort I et al., Flavonoid glucuronides from flowers of *Arnica montana*. Short lecture *Arzneipflanzenforschung*, Leiden, Niederlande, 1987

Paulsen E et al., Cosmetics and herbal remedies with compositae plant extracts - are they tolerated by Compositae-allergic patients? *Contact dermatitis*, 2008, 58, 15-23

Paulsen E, Contact sensitization from compositae-containing herbal remedies and cosmetics. *Contact Dermatitis*, 2002, 47, 189-198

Pirker C, et al., Cross-reactivity with Tagetes in Arnica contact eczema. *Contact Dermatitis*, 1992, 26, 217-219

Reider N et al., The seamy side of natural medicines: contact sensitization to Arnica (*Arnica montana* L.) and marigold (*Calendula officinalis* L.). *Contact dermatitis*, 2001, 45, 269-272

Ross SM, Osteoarthritis, a proprietary Arnica gel is found to be as effective as ibuprofen gel in osteoarthritis of the hands. *Holist Nurs Pract*, 2008, 22 (4), 237-239

Saluk-Juszak J et al., The effects of polyphenolic-polysaccharide conjugates from selected medical plants of asteraceae family on the peroxynitrite-induced changes in blood platelet proteins. Elsevier B.V., 2010, doi:10.1016

Schmidt TJ et al., Anti-trypanosomal activity of helenalin and some structurally related sesquiterpene lactones. *Planta med*, 2002, 68, 750-751

Schröder H et al., Helenalin and 11-alpha, 13-dihydrohelenalin, two constituents from *Arnica montana* L. inhibit human platelet function via thiol-dependent pathways. Institut für Pharmazeutische Biologie Düsseldorf, 1990

Spettoli E et al., Contact dermatitis caused by sesquiterpene lactones. *Contact Dermatitis*, 1998, 9 (1), 49-50

Tekko IA et al., Permeation of bioactive constituents from *Arnica montana* preparations through human skin in-vitro. *Journal of Pharmacy and Pharmacology*, 2006, 58, 1167-1176

Totonchi A, Guyuron B, A randomized, controlled comparison between Arnica and Seroids in the management of postrhinoplasty ecchymosis and edema. *PRSJournal*, 2007, 10.1097, 271-274

Wagner S et al., In vitro behaviour of sesquiterpene lactones and sesquiterpene lactone-containing plant preparations in human bile, plasma and human serum albumin solutions. *Planta med*, 2004, 70, 227-233

Wagner S et al., Skin penetration studies of Arnica preparations and of their sesquiterpene lactones. *Planta med*, 2004, 70, 897-903

Widrig R, Suter A, Saller R, Melzer J, Choosing between NSAID and Arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study. *Rheumatol Int*, 2007, 27, 585-591

Willuhn G et al., 6-O-Isobutyryl-tetrahydrohelenalin aus Blüten von *Arnica montana*. Short lecture Deutsche Pharmazeutische Gesellschaft, Freiburg, Pharm Ztg, 1981, 126, 2017

Willuhn G et al., Helenalin- und 11,13-Dihydrohelenalinester aus Blüten von *Arnica montana*. Kurzvortrag Deutsche Pharmazeutische Gesellschaft, Regensburg, Pharm Ztg, 1983, 49, 226-231

Woerdenbag HJ et al., Cytotoxicity of flavonoids and sesquiterpene lactones from Arnica species against the GLC4 and the COLO 320 cell lines. *Planta med*, 1994, 60, 434-437

References used but not cited in the Assessment report:

Alfredo PP et al., Effects of phonophoresis with *Arnica montana* onto acute inflammatory process in rat skeletal muscles: An experimental study. *Ultrasonics*, 2008, 49, 466-471

Ciganda C, Laborde A, herbal infusions used for induced abortion. *Journal of toxicology Clinical Toxicology*, 2003, 41, No 3, 235-239

Ekenäs C et al., Screening for anti-inflammatory activity of 12 Arnica (Asteraceae) species assessed by inhibition of NF-kB and release of human neutrophil elastase. *Planta med*, 2008, 74, 1789-1794

Ganzena M et al., Quantitative analysis of flavonoids and phenolic acids in *Arnica montana* L. by micellar electronic capillary chromatography. *Analytica chimica*, 2008, 614, 196-200

Hermann H-D, Willuhn G, Hausen BM, Helenalinmethacrylate, a new pseudoguaianolide from the flowers of *Arnica montana* L. and the sensitizing capacity of their sesquiterpene lactones. *Planta med*, 1978, 34, 299-304

Jäger C et al., Phytomedicines prepared from Arnica flowers inhibit the transcription factors AP-1 and NF-kB and modulate the activity of MMO1 and MMP13 in human and bovine chondrocytes. *Planta med*, 2009, 10-1055

Kolodziej H, Sesquiterpenlactone - Biologische Aktivität. Deutsche Apothekerzeitung, 1993, 133 20, 1795-1805

Machet L et al., Allergic contact dermatitis from sunflower (*Helianthus annuus*) with cross-sensitivity to Arnica. Contact D, 1993, 28, 184-200

Marcinek-Hüpen-Bestendonk C et al., Germacranoide, guaianoloide und xanthanolide from the flowers of *Arnica mollis* and an x-ray structure analysis of baileyan acetate. Planta med, 1990, 56, 104-109

Merfort I et al., Methylated flavonoids from *Arnica montana* and *Arnica chamissonis*. Short lecture Pharmazeutische Wissenschaften, München, 1983

Merfort I et al., Flavonoids from *Arnica montana* and *Arnica chamissonis*. Short lecture Arzneipflanzenforschung, Antwerpen, 1984

Merfort I et al., New flavonoid glycosides from Arnicae flos DAB 9. Short lecture Gesellschaft für Arzneipflanzenforschung Freiburg 1988, Braunschweig 1989

Paßreiter CM et al., Tussilagine and isotussilagine: two pyrrolizidine alkaloids in the genus arnica. 9th congress of Medical plant research, Saarbrücken, 1991

Paßreiter CM, Co-occurrence of 2-pyrrolidine acetic acid with the pyrrolizidines tussilaginic acid and isotussilaginic acid and their 1-epimers in Arnica species and *Tussilago farfara*. Phytochemistry, 1992, 31 (12), 4135-4137

Schempp CM, Schöpf E, Simon JC, Durch Pflanzen ausgelöste toxische und allergische Dermatitis (Phytodermatitis). Hautarzt, 2002, 53, 93-97

Staniuc AM et al., In-vitro antimicrobially activity of Romanian medical plants hydroalcoholic extracts on planktonic and adhered cells. National Institute for Biological Sciences, Bucharest, Romania

Verma N et al., Evaluation of inhibitory activities of plant extracts on production of LPS-stimulated pro-inflammatory mediators in J774 murine macrophages. Mol cell Biochem, 2010, 336, 127-135

Willuhn G, Arnika-Kontaktdermatitis und die sie verursachenden Kontaktallergene. Deutsche Apothekerzeitung, 1986, 38, 2038-2044

Willuhn G, Sesquiterpenlactone, potentielle Leitsubstanzen für die Arzneistofffindung Struktur und biologisch-pharmakologische Aktivitäten. Deutsche Apothekerzeitung, 1987, 48, 2511-2517